INDIGO Biosciences, Inc

10/19/2026

Contact us today to take advantage of this limited time offer and get 20% off screening services of more than $10,000 until November 20!*

https://hubs.la/Q04BzxJv0

10/15/2026

A recent publication titled "Long-Acting RXR Agonism Preserves Retinal Function and Modulates Inflammation in Diabetic Retinopathy" utilized INDIGO's PPARα and LXR Panel assays!

Read now by clicking on the link below 🎉

https://hubs.la/Q04BgHGv0

10/14/2026

By evaluating multiple relevant receptors in a consistent functional format, researchers can better understand the endocrine activity profile of a compound before advancing to more resource-intensive studies.

These results can help your team:

🧩 Characterize receptor-specific functional activity
💊 Compare compounds across a lead series
🔬 Identify unintended endocrine activity
🔍 Investigate unintended hormone receptor activity
🧪 Prioritize findings for additional characterization

Binding data can help show whether a compound interacts with a receptor. Functional data helps answer a related question: Does the compound activate or inhibit that receptor’s signaling?

INDIGO’s endocrine studies can include agonist or antagonist, concentration-response testing, comparative testing across compound series, and focused or expanded receptor panels.

Endocrine disruptor testing using human-relevant, functional nuclear receptor assays to identify hormone-mediated safety risk early.

10/12/2026

Contact us today to take advantage of this limited time offer and get 20% off compound screening services of more than $10,000 until November 20th!* https://hubs.la/Q04zWWLr0

10/09/2026

Rediscover INDIGO's RAR-related Orphan Receptor Alpha (ROR) Assays!

RORα and RORγ are nuclear receptors that regulate transcriptional programs involved in immune function, metabolism, development, and circadian biology. RORγ is important in Th17 cell differentiation and inflammatory signaling, while RORα has roles in metabolic regulation and circadian rhythm, making these receptors relevant to autoimmune disease, inflammation, metabolic disorders, and other areas of drug discovery.

The principal application of this reporter assay system is in the screening of test samples to quantify functional activity they may exert against the RORs.

Talk to one of our scientists today about our ROR assays! https://bit.ly/3U8f7fX

10/07/2026

Unintended activity of hormone receptors can raise important questions during drug discovery and development.

INDIGO Biosciences offers Endocrine Safety Screening using cell-based reporter assays to evaluate how compounds affect key receptors. Rather than measuring binding alone, INDIGO’s assays measure whether a compound activates or inhibits receptor-mediated signaling.

Whether you are comparing lead compounds or investigating an emerging endocrine signal, INDIGO’s endocrine panel screening can provide additional mechanistic context for your compound decisions.

Endocrine disruptor testing using human-relevant, functional nuclear receptor assays to identify hormone-mediated safety risk early.

10/05/2026

Contact us today to take advantage of this limited time offer and get 20% off compound screening services of more than $10,000 until November 20th!* https://bit.ly/4hH1Mmm

10/02/2026

Rediscover INDIGO's Androgen Receptor (AR) Assays!

The Androgen Receptor (AR) is a ligand-activated nuclear receptor that regulates gene expression involved in male reproductive development, muscle and bone biology, metabolism, and other androgen-responsive processes.

Because of its role in hormone signaling, AR is widely studied in prostate cancer, endocrine disorders, reproductive health, muscle biology, and endocrine disruption research.

The principal application of this reporter assay system is in the screening of test samples to quantify functional activity they may exert against the AR.

Talk to one of our scientists today about our AR assays! https://bit.ly/4e6dfeg

10/01/2026

Contact us today to take advantage of this limited time offer and get 20% off screening services of more than $10,000 until November 20!*

https://bit.ly/3Vp9SJ4

09/30/2026

Your compounds and research objectives are specific to your program. Your NHR screening strategy should be, too.

Bring us your compounds, intended targets, and research questions. INDIGO’s scientists can help translate your research priorities into a customized panel designed to deliver actionable functional data.

Together, we can identify the relevant receptors, define the appropriate screening approach, and develop a study that supports your next decision.

Tell us what you need to evaluate. We’ll help you build the study to move it forward! https://hubs.la/Q04yJl3_0